Already Registered? Click Here

Liver disease is a rising cause of mortality worldwide. Current drug discovery studies rely on primary human hepatocytes and hepatocellular cancer cells. However, these cells have limitations, including short lifespan, rapid loss of function, and malignant origin, leading to compromised model translatability. As a result, most therapeutics fail long before they enter the clinic.

Hepatocytes derived from induced pluripotent stem cells (iPSCs) successfully overcome these challenges and provide a sustainable in vitro platform for large-scale preclinical drug studies.

In this GEN webinar, our speakers will present new research into iPSC-derived hepatocyte models, how they compare to liver cancer cells lines, and why they are a better model for large-scale preclinical drug studies. During the webinar, you’ll learn about DefiniGEN’s highly characterized iPSC-derived hepatocytes (Opti-HEP) and how they provide a sustainable in vitro platform for disease modeling, ADME, and toxicology screening.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.